Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00466440 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study With Enzastaurin Plus Chemotherapy or Placebo Plus Chemotherapy for Prostate Cancer Patients
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 108
- Enrollment target
NCT00466440 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 108 participants.
The verdict
NCT00466440, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 108 participants
- Enrollment target
Study Summary
The purpose of the study is to compare the response rates for prostate cancer patients taking chemotherapy plus enzastaurin versus chemotherapy plus placebo.
Interventions
- DRUG placebo
- DRUG prednisone
- DRUG docetaxel
- DRUG enzastaurin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2007-06 |
| Est. Completion | 2010-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00466440
The ClinicalTrials.gov registry entry for NCT00466440 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 108 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which placebo is the first listed.
NCT00466440 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00466440 about?
NCT00466440 is a clinical study titled "A Phase 2 Study With Enzastaurin Plus Chemotherapy or Placebo Plus Chemotherapy for Prostate Cancer Patients". The purpose of the study is to compare the response rates for prostate cancer patients taking chemotherapy plus enzastaurin versus chemotherapy plus placebo.
What is the current status of trial NCT00466440?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 108 participants. The study started on 2007-06. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00466440?
The interventions under investigation include: placebo (DRUG), prednisone (DRUG), docetaxel (DRUG), enzastaurin (DRUG).
Who is sponsoring clinical trial NCT00466440?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.